

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

APPROPRIATE TO 21 MAY 2006
Complete if Known

Substitute for form 1449B/PTO				Application Number		Unassigned
INFORMATION DISCLOSURE				Filing Date		10/26/2005
STATEMENT BY APPLICANT				First Named Inventor		William VAINCHENKER
Date Submitted: MAY 24 2006				Group Art Unit		Unassigned
(use as many sheets as necessary)				Examiner Name		Unassigned
Sheet	1	of	1	Attorney Docket Number		065691-0445

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,914,393	A	Coleman et al.	06/22/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A2	Database UniProt Online, June 7, 2005, "Janus kinase 2.", XP002369149, retrieved from EBI accession no. UNIPROT:Q506Q0.		
	A3	JAMES et al., "A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera," Nature, vol. 434, no. 7037, April 2005, pp. 1144-1148.		
	A4	BAXTER et al., The Cancer Genome Project, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders," The Lancet, vol. 365, no. 9464, march 19, 2005, pp. 1054-1061.		
	A5	UGO et al., "Multiple signaling pathwasay are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera," Experimental Hematology, vol. 32, no. 2, February 2004, pp. 179-187.		
	A6	SALTZMAN et al., "Cloning and characterization of human JAK-2 kinase: High mRNA expression in immune cells and muscle tissue," Biochemical and Biophysical Research Communications, vol. 246, no. 3, May 29, 1998, pp. 627-633.		
	A7	PAUL, H.L., "Towards a molecular understanding of polycythemia rubra vera," European Journal of Biochemistry, vol. 267, no. 12, June 2000, pp. 3395-3401.		

Examiner Signature	/Sheridan Swope/	Date Considered	09/25/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.